Story perspectives

Regeneron Set to Acquire 23andMe for $256 Million

5/22/2025

28 4

Summary

Story summary

Regeneron Pharmaceuticals intends to acquire 23andMe for $256 million, pending court and regulatory approvals, expected by Q3 2025.
The acquisition encompasses 23andMe’s Personal Genome Service, Total Health, Research Services, and biobank, excluding Lemonaid Health.
Regeneron will uphold 23andMe’s privacy policies and ethical data practices, overseen by a Customer Privacy Ombudsman.
This move aims to bolster Regeneron's genetics-focused research and drug development while ensuring consumer service continuity.

1 of 1

Story summary

Regeneron Pharmaceuticals intends to acquire 23andMe for $256 million, pending court and regulatory approvals, expected by Q3 2025.
The acquisition encompasses 23andMe’s Personal Genome Service, Total Health, Research Services, and biobank, excluding Lemonaid Health.
Regeneron will uphold 23andMe’s privacy policies and ethical data practices, overseen by a Customer Privacy Ombudsman.
This move aims to bolster Regeneron's genetics-focused research and drug development while ensuring consumer service continuity.